Oncology and Carcinogenesis articles for Sun Yat-sen University (SYSU), China

Time frame: 1 June 2025 - 30 May 2026

View topic

Count: 193

Article ‘Count’ for Oncology and Carcinogenesis.

Journal Count Share
11 5.43
Arginine Polymer-Based Nanoplatform Facilitates Oral Co-Delivery of Antibody/Antigen for Robust Oral Immunotherapy in Orthotopic Colon Cancer 0.35
Hydration-Driven Self-Gelling Particulate Embolic Agent for Precise and Stable Occlusion of Hemorrhagic Vessels with Collateral Circulation 1.00
Oxygen Self-Sufficient Ir–MnII/III Coordination-Assembled Nanoparticles Evoke Apoptosis and Ferroptosis for Boosting Hypoxic Melanoma Photoimmunotherapy 0.42
H2S-Activable BiFeO3–x Nanocatalysts for Ferroptosis-Driven Cancer Immunotherapy 0.06
Photosynthetic Plant-Derived Nanovesicles Precisely Amplify Photodynamic Effect by Light-Activated Oxygen Generation for Enhanced Cancer Photoimmunotherapy 0.16
Inhalable Fibroin Hybrid Liposomes for the Targeted Treatment of Lung Adenocarcinoma via Autophagy-Enhanced Ferroptosis 0.13
Prolonged Release of Bacillus Calmette–Guérin by Floating Microbubbles to Enhance Intravesical Immunotherapy for Bladder Cancer 1.00
Engineered Bacteria-Nanoparticle Conjugate Reprograms Immunosuppressive Niche via Dendritic Cell-Centric Innate-Adaptive Immune Coupling 0.06
Self-Driving and Detachable Lab-Microrobots Tailor Drug Delivery for Closed-Loop Stimulation of the Antitumor Immune Cycle 0.71
Nanoigniter-Integrated Microneedle Patches for Boosted Photothermal-Mediated Multimodal Therapy: In Situ Tumor Microenvironment Igniting Strategy 0.67
Cognate Nanovaccine Promotes Tertiary Lymphoid Structures Function and Strengthens Immune Cell Cross-Talk by Targeting Exhausted T Cells in Nonimmunogenic Cancers 0.89
3 1.27
Precision treatment with artificial intelligence assisted subtyping enhances therapeutic efficacy in HR+/HER2− breast cancer: The LINUXtrial 0.02
T-cell Hitchhiking Nanodrug Activates the cGAS-STING Signaling Pathway for Enhanced Cancer Immunotherapy 0.45
Nanoparticle-induced excessive mitophagy combined with immune checkpoint blockade for enhanced cancer immunotherapy 0.80
6 2.10
Single‐Atom Magnesium Nanozymes Orchestrate Redox Homeostasis and Controlled Autophagy for Glioblastoma Therapy 0.18
Stimuli‐Responsive Heterobimetallic Prodrug Platform Enables In Situ Copper Complex Synthesis and Photosensitizer Activation for Targeted Chemo‐Photodynamic‐Immunotherapy 1.00
Biodegradable Nanomissile Targeting the NKG2D/NKG2DL Axis Boosts Photo-Immunotherapy by T Cell plus NK Cell Attack 0.09
Closed-Loop Brain–Immune–Tumor Modulation via Magnetoelectric Nanocatalysis for Synergistic Cancer Immunotherapy 0.09
Heteronuclear Single‐Atom Nanozymes Overcome Radiotherapy Resistance via Synergistic Multi‐Enzyme Activities 0.33
From Exciton Dynamics to Cell Fate: A Carbon Dot Based NIR Photocatalytic Platform for Pyroptosis via Self‐Trapped Excitons 0.40
4 2.70
Microwave-Actuated Hot-Carrier/Polarization Triggers Catalysis to Coordinate Staphylococcus aureus Ribosome Stalling and Treat Deep-Seated Infections 0.06
Immuno-Packed T-Cell-Fusogenic Liposome Empowers Adoptive T Cell Therapy for Solid Tumor Treatment 0.71
Synergistic Copper‐Coordination/Glutathione Reduction Drives an In Situ Type II‐to‐Type I Photodynamic Switch in Iridium‐Based Photosensitizer Nanocomposites for Potentiated Cancer Immunotherapy 0.97
Engineering CRISPR System‐Based Bacterial Outer Membrane Vesicle Potentiates T Cell Immunity for Enhanced Cancer Immunotherapy 0.96
1 0.05
Pre-diagnostic Body Mass Index Trajectories and Associations with Lung Cancer Risk 0.05
2 1.63
SYT8 Drives Colorectal Cancer Progression and Immune Evasion via the SETD1A-H3K4me3 Axis 0.69
NSUN5 Mediates Resistance to Doxorubicin via Upregulation of DNA Damage Repair Proteins BRCA2 and BRIP1 in Colorectal Cancer 0.93
4 2.26
Phosphoproteins Identification on Stretchable Photonic Crystal for Cervical Cancer Assessment 0.33
Sensitive Imaging of Intracellular Long Noncoding RNAs In Situ in Living Cells Based on Synergistic Dual Hybridization Chain Reaction 0.92
A New Biomarker for Predicting the Abscopal Effect: Quantifying Polyclonal Effector Tumor Antigen-Specific T Cells by Using Nanoparticles Loading Whole Tumor Antigens 0.07
Dynamic Monitoring of Chelatable Zinc on Endoplasmic Reticulum During Immunogenic Cell Death by TPPLIM Using a Theranostic Ir(III) Complex 0.94
5 1.32
Mitochondria-Targeting Iridium(III) Complexes Induce PANoptosis and Ferroptosis for Boosting Chemoimmunotherapy Against Immune-Desert Colorectal Cancer 0.72
A Cell‐Resolved Ultrastable Biosensor Enables One‐Step Detection of Gene‐Fusion Transcripts in Unprocessed Whole Blood 0.03
Organoplatinum(II) J‐Aggregates with Prolonged Triplet Lifetimes for Enhanced Photodynamic and Photocatalytic Therapy 0.13
Boosting Cancer Chemoimmunotherapy with Mitochondria-Targeting Iridium(III)-Based Immunogenic Oncosis Inducers 0.28
Simultaneously Enhancing NIR‐II Emission, Type‐I, and Type‐II Photosensitization Through Acceleration of Charge‐Separated‐State Formation for Tumor Phototheranostics 0.17
1 0.76
Association of Recurrence with a Tumor-informed Personalized ctDNA Detection Approach in Resectable Colorectal Cancer: Results of a Prospective Observational Study. 0.76
7 3.51
Endocytic evasion confers resistance to antibody-drug conjugates therapy in cancer 0.77
JYP0322, a highly selective and brain-penetrant ROS1 inhibitor, overcomes ROS1G2032R resistance mutation in NSCLC: The first-in-human phase 1 trial 0.24
Dissecting genetic and immune drivers of heterogeneous responses to neoadjuvant immunochemotherapy in gastric cancer 0.88
Lipid oxidation reprogramming in cancer-associated fibroblasts enhances CD8+ T cell cytotoxicity and therapeutic response 0.51
Paneth-like transition drives resistance to dual targeting of KRAS and EGFR in colorectal cancer 0.73
Remodeling of T and endothelial cells during total neoadjuvant therapy in rectal cancer 0.17
Neoadjuvant treatment of IBI310 plus sintilimab in locally advanced MSI-H/dMMR colon cancer: A randomized phase 1b study 0.21
11 4.46
Comprehensive Multi-Omic Characterization of Perineural Invasion in Cervical Cancer Reveals Diagnostic Markers, Molecular Drivers, and Therapeutic Strategies 0.54
Fusion of Tumor Cells with Lipid-Associated Macrophages Drives Metastatic Progression of Breast Cancer 0.22
Inhibition of GSK3 and TSC2 Mediates the Oncogenic Activity of AKT in Hepatocellular Carcinoma 0.02
RORγ Hijacks HIF-1α to Promote Peritoneal Metastasis of Gastric Cancer. 0.65
FADD Activation in Hepatocellular Carcinoma Potentiates CD8+ T-cell Responses and Sensitizes to Immune Checkpoint Inhibitors 0.13
Intracellular Interleukin-1α in Peritumoral Monocytes Induces IL8 Production and Inhibits Mitophagy to Promote Stemness and Metastasis of Hepatocellular Carcinoma. 1.00
Neuropeptide Precursor VGF Promotes Neuroendocrine Differentiation and Cancer-Associated Fibroblast Activation in Small Cell Lung Cancer. 0.81
Large-scale Characterization of Orthotopic Cell Line–Derived Xenografts Identifies TGFβ Signaling as a Key Regulator of Breast Cancer Morphology and Aggressiveness 0.02
Targeting LTBP2 Derived from Cancer-Associated Fibroblasts Sensitizes Esophageal Squamous Cell Carcinoma to Chemotherapy 0.71
Cancer-Associated Fibroblasts Foster a High-Lactate Microenvironment to Drive Perineural Invasion in Pancreatic Cancer 0.14
SMYD3 Activates Fatty Acid β-Oxidation to Promote Self-Renewal of Leukemia Stem Cells 0.22
1 0.03
An iPSC-derived CD19/BCMA CAR-NK therapy in a patient with systemic sclerosis 0.03
1 0.05
Bacteroides fragilis promotes chemoresistance in colorectal cancer, and its elimination by phage VA7 restores chemosensitivity 0.05
3 1.85
The S100A8/A9 complex promotes food intake and prevents adipose tissue loss during cancer cachexia in mice 0.03
Serotonin-licensed macrophages potentiate chemoresistance via inositol metabolic crosstalk in ovarian cancer 0.88
Extracellular vesicles from obese visceral adipose promote pancreatic cancer development and resistance to immune checkpoint blockade therapy 0.94
1 0.07
MMRN1-EGFR drives sialylglycan-Siglec immune evasion in AML leukemia stem cells 0.07
1 0.93
A thiazolo[5,4-d]thiazole-bridged dinuclear iridium(iii) photosensitizer induces ferroptosis for boosting photoimmunotherapy against hypoxic melanoma 0.93
2 1.31
Phosphorescent iridium complexes activated by endogenous zinc as a mitochondrial DNA nuclease for stimulation of the cGAS-STING pathway 0.90
Photo-uncaging of a ferrocene-bridged dinuclear iridium(scpiii/scp) complex for three-photon photoimmunotherapy against hypoxic melanoma 0.42
2 0.68
Unleashing T cell surveillance for the eradication of quiescent persister tumor cells resistant to neoadjuvant chemotherapy 0.05
Long-range deployment of tumor-antigen-specific cytotoxic T lymphocytes inhibits lung metastasis of breast cancer 0.63
7 2.54
PTEN deficiency impairs MHC-I-mediated tumour immunity via NRF2-dependent autophagy in microsatellite stable colorectal cancer 0.92
SDC1+ CAFs secreting CTGF drive tumour metastasis via FGFR3 signalling in cancers 0.75
Prospective evaluation of radical surgery for adenocarcinoma of oesophagogastric junction: real-world insights from the CLAEG study 0.08
Targeting cancer stem cells enhances multikinase inhibitor therapy in metabolic dysfunction-associated steatotic liver disease-related hepatocellular carcinoma 0.11
Alleviated T cell exhaustion and SLC1A3-mediated stroma-remodelling dictate chemoimmunotherapy efficacy in oesophageal squamous cell carcinoma 0.50
Comparative risk of high-risk neoplasia after polypectomy among individuals aged below 50 years versus 50 years and older 0.07
Pericyte drives the formation of circulating tumour cell-neutrophil clusters to promote colorectal cancer metastasis 0.10
3 1.87
Low-dose chemotherapy remodels hepatic immune landscape and potentiates anti-tumor response to immune checkpoint blockade in cholangiocarcinoma. 0.80
Antiangiogenic therapy combined with immune checkpoint blockade mediates CCR7+CD8+ T-cell entry into HCC through high endothelial venules. 0.94
Arid1a deficiency promotes hepatocyte hyperpolyploidy and drives intrahepatic cholangiocarcinoma in mice. 0.13
1 0.92
Efflux of N1-acetylspermidine from hepatoma fosters macrophage-mediated immune suppression to dampen immunotherapeutic efficacy 0.92
1 0.04
Type I Rhodamine-Sensitized Iridium(III) Complex Photosensitizers Activate Pyroptosis for Hypoxic Photodynamic Immunotherapy 0.04
2 1.88
Landscape of splicing factors in early-onset gastric cancer reveals SRSF1 as a key driver of oxaliplatin resistance 1.00
KRASG12D mutation promotes pancreatic tumorigenesis by suppressing sirtuin three via the guanine nucleotide exchange factor RCC1 0.88
1 0.85
An Interpretable Machine Learning Model for Predicting Occult Central Lymph Node Metastasis in Papillary Thyroid Cancer 0.85
8 6.54
Targeting RANKL-independent osteoclastogenesis overcomes denosumab resistance in models of ER+ breast cancer bone metastasis 0.76
IL-6 receptor blockade impedes proinflammatory atypical Treg subset associated with immune checkpoint inhibitor-induced inflammatory arthritis 0.16
Tescalcin is a phagocytic checkpoint driving immune escape and limiting immunotherapeutic efficacy in hepatocellular carcinoma 1.00
The allosteric IDH1 inhibitor ivosidenib overcomes chemoresistance in intrahepatic cholangiocarcinoma models expressing wild-type IDH1 0.90
EGFR activation disrupts immunotherapy response via SHP2-mediated suppression of tumor-intrinsic response to IFN-γ 0.77
Vessels encapsulating tumor clusters promote non-invasive metastasis of hepatocellular carcinoma by shaping an immunosuppressive microenvironment 1.00
LC3-dependent intercellular transfer of phosphorylated STAT1/2 elicits CXCL9+ macrophages and enhances radiation-induced antitumor immunity 1.00
PIM3-mediated phosphorylation stabilizes myeloid leukemia factor 2 to promote metastasis in osteosarcoma 0.94
9 2.32
Tislelizumab Combined With Induction Chemotherapy and Concurrent Chemoradiotherapy in Locally Advanced Esophageal Squamous Cell Carcinoma: A Multicenter, Randomized, Phase II Trial (EC-CRT-002). 0.83
Izalontamab Brengitecan in Locally Advanced or Metastatic Non-Small Cell Lung Cancer With Actionable Genomic Alterations Outside of Classical EGFR Mutations: A Phase Ib Study. 0.63
Trastuzumab Rezetecan in Human Epidermal Growth Factor Receptor 2-Expressing Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma and Colorectal Cancer: A Multicenter, Open-Label, Phase I Trial. 0.12
Transarterial Chemoembolization Combined With Camrelizumab and Rivoceranib for Unresectable Hepatocellular Carcinoma (CHANCE2005/CARES-005): A Randomized Phase II Trial. 0.03
Neoadjuvant Chemotherapy With CAPOX Versus Chemoradiation for Locally Advanced Rectal Cancer With Uninvolved Mesorectal Fascia (CONVERT): Final Results of a Phase III Trial. 0.39
Neoadjuvant Taxane Plus Trastuzumab and Pertuzumab With or Without Carboplatin in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: The Randomized Noninferiority Phase III neoCARHP Trial. 0.06
Randomized Parallel-Group Phase II Study (NEOTERIC) of Atezolizumab With or Without Tiragolumab After Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer. 0.15
Efficacy and Safety of BL-B01D1 in Patients With Locally Advanced or Metastatic Urothelial Carcinoma: A Phase II Clinical Trial. 0.05
Camrelizumab Plus Famitinib versus Camrelizumab Alone and Investigator's Choice of Chemotherapy in Recurrent or Metastatic Cervical Cancer: A Randomized, Phase II Study. 0.05
1 0.31
Specific loading of oncolytic VSV on CAR enhances CAR-T cell signaling and antitumor activity 0.31
3 0.16
Updated data from IMbrave050: Adjuvant atezolizumab plus bevacizumab for high-risk hepatocellular carcinoma 0.08
Targeting cell-state plasticity driven by FOXM1/CEBPB axis disrupts developmental heterogeneity and therapeutic resistance in hepatocellular carcinoma 0.08
Mevalonate pathway promotes liver cancer by suppressing ferroptosis through CoQ10 production and selenocysteine-tRNA modification 0.01
2 1.04
Two-Dimensional Iridium(III)–Carbon Nitride Nanocomplexes Induce Simultaneous Oncosis and Necroptosis for Synergistic Chemo- and Sono-Immunotherapy in Hypoxic Melanoma 0.40
Dibenzocyclooctyne Conjugation Enhances Antigen Cross-Presentation and T-Cell Killing for Potent Cancer Vaccines 0.65
1 0.17
Electro-acupuncture for quality of life during adjuvant chemotherapy in gastric cancer: a randomized trial 0.17
1 0.71
UMP functions as an endogenous regulator of NR4A1 to control gastric cancer progression 0.71
1 0.09
Intracellular Bacteria-Mimicking Whole-Cell Cancer Vaccine Potentiates Immune Responses via Concurrent Activation of NLRP3 Inflammasome and STING Pathway 0.09
3 1.16
Risk-adaptive therapy guided by dynamic ctDNA in nasopharyngeal carcinoma 0.81
Polyclonal origins of human premalignant colorectal lesions 0.02
SPP1 is required for maintaining mesenchymal cell fate in pancreatic cancer 0.33
6 3.37
Peritumoural adipose tissue promotes ferroptosis resistance by 3-hydroxykynurenine-mediated suppression of ferritinophagy 0.68
The lncRNA DAMER selectively guides mA-dependent regulation of ATF4 and asparagine metabolism under nutrient stress in cancer 0.57
Peritumoural adipose tissue drives immune evasion in colorectal cancer via adipose–mesenchymal transformation 0.71
THY1 cancer stem cells drive metastasis through a pseudohypoxic state shaped by neutrophil-derived mitochondria 0.83
SLC2A1+ tumour-associated macrophages spatially control CD8+ T cell function and drive resistance to immunotherapy in non-small-cell lung cancer 0.05
Defining heterogeneity in core regulatory circuitry reveals HOXB3 condensation as a potential target in glioblastoma 0.54
1 0.18
Deacetylase-independent HDAC1 condensation defines temozolomide response in glioblastoma 0.18
32 14.37
Iron overload in the tumor microenvironment induces CD8+ T cell ferroptosis and dysfunction 0.23
Durvalumab plus HAIC-FOLFOX followed by maintenance durvalumab for hepatocellular carcinoma with major portal invasion: phase 2 DurHope study 1.00
Neoadjuvant toripalimab plus CapeOX in locally advanced Epstein-Barr virus-associated gastric or gastroesophageal junction adenocarcinoma: a phase Ⅱ trial 0.10
Genetic landscape and functional exploration of kidney cancer predisposition in cross-ancestral populations 0.06
Quizartinib and omacetaxine mepesuccinate combination therapy in FLT3-ITD AML: a phase II trial 0.03
Targeting a super-enhancer induced aldehyde dehydrogenase metabolic loop mitigates CDK4/6 inhibitor resistance in estrogen receptor-positive cancers 0.94
Multitrait GWAS and functional validation reveal genetic loci for gastric cancer 0.05
Targeting leucine-rich repeat kinase 2 overcomes resistance to oncolytic herpes simplex virus-based therapies in glioblastoma 0.03
Amelioration of colorectal cancer-associated fibroblasts in immunosuppressive microenvironment by ferroptosis-based nanotherapy 0.06
STING synergizes with TOX suppressing HO-1 expression to trigger ferroptosis in tumor-infiltrating CD8+ T cell and immunotherapy resistance 1.00
Afuresertib plus fulvestrant for pretreated HR-positive, HER2-negative, advanced breast cancer: a phase Ib trial 0.08
Combined targeted and epigenetic-based therapy enhances antitumor immunity by stabilizing GATA6-dependent MHCI expression in pancreatic ductal adenocarcinoma 0.01
CDK2 inhibitor BLU-222 synergizes with CDK4/6 inhibitors in drug resistant breast cancers through p21/p27 induction 0.02
Neoadjuvant chemoradiotherapy plus sintilimab in proficient mismatch repair locally advanced rectal cancer with intermediate/high-immunoscore (SILAR): a single-arm phase II trial 1.00
NALIRIFOX versus gemcitabine plus nab-paclitaxel in Chinese patients with advanced pancreatic adenocarcinoma: a randomized, open-label phase II trial 0.03
Osimertinib with or without savolitinib as first-line treatment for MET-aberrant, EGFR-mutant NSCLC: randomized phase 2 trial (FLOWERS) 0.06
Fruquintinib plus sintilimab in patients with advanced endometrial cancer with mismatch-repair proficient status: a multicenter, single-arm, phase Ib/II trial 0.03
AAK1 activation-mediated iron trafficking drives ferroptotic cell death 0.90
αPD-1-conjugated acid-cleavable nanodrugs overcomes cellular immunotherapy barriers in pancreatic tumors 0.91
Targeting of the m6A eraser ALKBH5 suppresses stemness and chemoresistance of colorectal cancer 0.11
Inhibiting B cells enhances the efficacy of STING agonism or immune checkpoint blockade in hepatocellular carcinoma 0.05
Targeting TNK2/ACK1 reverses the immunosuppressive tumor microenvironment and synergizes with immunochemotherapy in pancreatic cancer 0.04
Induction chemotherapy plus camrelizumab followed by concurrent chemoradiotherapy in unresectable locally advanced esophageal squamous cell carcinoma: a single-arm phase II trial 0.94
Wild-type KRAS activation drives evasion of interferon-mediated immunity and resistance to immunotherapy in hepatocellular carcinoma 0.05
Chromatin looping-based CRISPR screen identifies TLK2 as chromatin loop formation regulator in cancer stemness plasticity 0.89
PROCR diminishes the efficacy of radiation by impairing T-cell-mediated antitumour immunity 1.00
Lung metastasis and recurrence is mitigated by CAR macrophages, in-situ-generated from mRNA delivered by small extracellular vesicles 0.75
Pericytes promote metastasis by regulating tumor local vascular tone and hemodynamics 0.04
AR+TREM2+ macrophage induced pathogenic immunosuppression promotes prostate cancer progression 1.00
Transdifferentiation of tongue muscle cells into cancer-associated fibroblasts in response to tongue squamous cell carcinoma 1.00
Androgen receptor promotes arachidonic acid metabolism and angiogenic microenvironment in AFP-negative hepatocellular carcinoma 0.95
Suppression of multiple mouse models of refractory malignancies by reprogramming IL-18 ligand-receptor interaction 1.00
1 0.86
Single-cell and spatial transcriptomics reveal mechanisms of radioresistance and immune escape in recurrent nasopharyngeal carcinoma 0.86
1 0.05
Succinate drives gut inflammation by promoting FOXP3 degradation through a molecular switch 0.05
4 0.88
Immunotherapy and senolytics in head and neck squamous cell carcinoma: phase 2 trial results 0.59
First-line sacituzumab tirumotecan with tagitanlimab in advanced non-small-cell lung cancer: a phase 2 trial 0.13
CLDN18.2–targeting antibody–drug conjugate IBI343 in advanced gastric or gastroesophageal junction adenocarcinoma: a phase 1 trial 0.03
The antibody–drug conjugate SHR-A1904 for targeting CLDN18.2 in advanced gastric or gastroesophageal junction cancer: a phase 1 trial 0.14
1 0.82
An encyclopedic regulatory and functional atlas of RNA interactomes 0.82
1 0.23
Enhancing antitumour nanovaccine efficacy via integrated cholesterol modulation in situ 0.23
2 1.05
Architecture of the human KICSTOR and GATOR1–KICSTOR complexes 0.05
TRIM21 and OTUD6A orchestrate AKT K27-linked atypical ubiquitination to modulate cancer chemoresistance 1.00
1 1.00
METTL14 integrates tumor-derived SAM to drive parabrachial epigenetic rewiring in pancreatic cancer 1.00
1 0.11
Acoustic delivery of indocyanine green via biosynthetic gas vesicles for tumor photothermal therapy 0.11
1 1.00
Optimal minimal residual disease threshold in pediatric acute myeloid leukemia: A retrospective cohort study based on the TARGET database. 1.00
5 1.19
Loss of UFL1 drives chromosome instability and tumorigenesis of prostate cancer 0.10
Structure-guided design of 7-azaindole DNMT1 inhibitors active against hypomethylating agent–resistant acute myeloid leukemia 0.06
HPV16 E6 oncoprotein promotes microhomology-mediated viral integration by increasing PolΘ protein expression 0.08
CRISPR screens identify the ATPase VCP as a druggable therapeutic vulnerability in cholangiocarcinoma 0.04
USP14-mediated metabolic competition impairs CD8+ T cell immunosurveillance in hepatocellular carcinoma 0.91
1 1.00
MRI-based Middle Neck Involvement in Stage N1-N2 Nasopharyngeal Carcinoma: A Marker for Risk Stratification. 1.00
3 0.73
In vivo membrane engineering traps Gd-based MRI contrast agents for detecting microhepatocellular carcinoma 0.21
Intratumoral Parvimonas micra promotes esophageal squamous cell carcinoma via p-cresol–induced Treg differentiation 0.01
Human iPSC-based breast cancer model identifies S100P-dependent cancer stemness induced by BRCA1 mutation 0.50
5 1.22
Phase separation–based HTS identifies cobimetinib as a YAP-TEAD inhibitor that suppresses hyperactivated YAP-induced cancer progression 0.03
Uncovering BAP1 deubiquitination landscape enhances mechanism elucidation and therapeutic precision for BAP1-deficient pancancers 0.08
Site-specific methylation of SRSF2P95H by SETD2 inhibits MDSC-mediated proinflammatory niche formation in mouse models of myelodysplastic syndrome 0.05
Rb1 deficiency induces synthetic lethality with ATR and PKMYT1 coinhibition in breast cancer cell lines and patient-derived xenografts 0.06
Targeting SIRT2 induces MLH1 deficiency and boosts antitumor immunity in preclinical colorectal cancer models 1.00
4 1.05
Medial retropharyngeal nodal region sparing radiotherapy in nasopharyngeal carcinoma: five year analysis of open label, non-inferiority, multicentre, randomised phase 3 trial 0.81
Pyrotinib or placebo in combination with trastuzumab and docetaxel for HER2 positive metastatic breast cancer: long term survival results from randomised phase 3 PHILA trial 0.07
Camrelizumab plus CAPOX with camrelizumab based maintenance versus CAPOX alone as initial treatment for gastric or gastro-oesophageal junction adenocarcinoma: randomised phase 3 trial 0.06
Sacituzumab tirumotecan versus docetaxel for previously treated EGFR-mutated advanced non-small cell lung cancer: multicentre, open label, randomised controlled trial 0.11
5 0.26
Pimicotinib versus placebo for tenosynovial giant cell tumour (MANEUVER): an international, randomised, placebo-controlled, phase 3 trial 0.04
Savolitinib plus osimertinib versus chemotherapy for advanced, EGFR mutation-positive, MET-amplified non-small-cell lung cancer in China (SACHI): interim analysis of a multicentre, open-label, phase 3 randomised controlled trial 0.03
Izalontamab brengitecan, an EGFR and HER3 bispecific antibody–drug conjugate, versus chemotherapy in heavily pretreated recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 study in China 0.12
Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (HARMONi-6): a randomised, double-blind, phase 3 trial 0.02
Efficacy and safety of selumetinib in adults with neurofibromatosis type 1 and symptomatic, inoperable plexiform neurofibromas (KOMET): a multicentre, international, randomised, placebo-controlled, parallel, double-blind, phase 3 study 0.05
1 0.20
Thyroid cancer in adolescents and young adults: a population-based study in 185 countries worldwide 0.20
4 0.73
Metronomic capecitabine as extended adjuvant chemotherapy for early triple-negative breast cancer (SYSUCC-001): updated 10-year outcomes and post-hoc exploratory biomarker analysis from a randomised, phase 3 trial 0.60
Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): final analysis of a randomised, open-label, international, phase 3 study 0.06
Fuzuloparib with or without apatinib in patients with HER2-negative metastatic breast cancer with germline BRCA1/2 mutations (FABULOUS): interim analysis of a multicentre, three-arm, open-label, randomised, phase 3 trial 0.04
First-line benmelstobart plus anlotinib versus sunitinib in advanced renal cell carcinoma (ETER100): a multicentre, randomised, open-label, phase 3 trial 0.02
3 0.22
Trastuzumab Deruxtecan in Residual HER2-Positive Early Breast Cancer 0.03
Sacituzumab Tirumotecan in EGFR-TKI–Resistant, EGFR-Mutated Advanced NSCLC 0.09
Disitamab Vedotin plus Toripalimab in HER2-Expressing Advanced Urothelial Cancer 0.10

Numerical information only (in the tables above) is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International.